Novartis shutters MorphoSys sites, lays off staff
BioPharma Dive - 19 Dec 2024Novartis shutters MorphoSys sites, lays off staff ...
morphosys
Novartis shutters MorphoSys sites, lays off staff ...
Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years
Fierce Biotech - 29 Oct 2024Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years ...
Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation
Fierce Pharma - 19 Dec 2024Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation ...
Novartis says 330 jobs hit as it closes MorphoSys sites
Reuters - 19 Dec 2024Novartis says 330 jobs hit as it closes MorphoSys sites ...
Pelabresib delay prompts Novartis to close MorphoSys units, 330 jobs hit
FirstWord Pharma - 19 Dec 2024Pelabresib delay prompts Novartis to close MorphoSys units, 330 jobs hit ...
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
BioSpace - 19 Dec 2024Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs ...
Bill Meury brings new perspective to Incyte as Hoppenot retires; Ex-MorphoSys CEO leads revitalized Vor Bio
Endpoints News - 27 Jun 2025Bill Meury brings new perspective to Incyte as Hoppenot retires; Ex-MorphoSys CEO leads revitalized Vor Bio ...
Morphosys’ antibody still shining – for J&J
European Biotechnology Magazine - 07 Apr 2025Morphosys’ antibody still shining – for J&J ...
Novartis sheds MorphoSys staff, sites after pelabresib delay
Pharmaphorum - 19 Dec 2024Novartis sheds MorphoSys staff, sites after pelabresib delay ...
Swiss pharma giant Novartis to close biotech firm Morphosys
SWI swissinfo.ch - 19 Dec 2024Swiss pharma giant Novartis to close biotech firm Morphosys ...
MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
ACCESS Newswire - 25 Jun 2025MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis ...
Biogen refreshes its C-suite; Novartis writes down MorphoSys assets
BioPharma Dive - 29 Oct 2024Biogen refreshes its C-suite; Novartis writes down MorphoSys assets ...
MorphoSys AG Finalizes Delisting After Novartis Acquisition
TipRanks - 05 Aug 2024MorphoSys AG Finalizes Delisting After Novartis Acquisition ...
Novartis: launch of Morphosys drug by could be 2027 or later
Reuters - 21 Nov 2024Novartis: launch of Morphosys drug by could be 2027 or later ...
Novartis gains global rights to Galapagos, MorphoSys' experimental atopic dermatitis drug MOR106
FirstWord Pharma - 17 Apr 2025Novartis gains global rights to Galapagos, MorphoSys' experimental atopic dermatitis drug MOR106 ...
PharmaEssentia nabs MorphoSys GM Horvat to lead its commercial team
Fierce Pharma - 06 Dec 2024PharmaEssentia nabs MorphoSys GM Horvat to lead its commercial team ...
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
ACCESS Newswire - 26 Apr 2025MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act ...
Novartis takes $800M MorphoSys writedown mere months after closing acquisition
Endpoints News - 29 Oct 2024Novartis takes $800M MorphoSys writedown mere months after closing acquisition ...
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
ACCESS Newswire - 25 Jan 2025Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting ...